Silence Therapeutics plc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
8. Benefit from R&D credit
An additional $2.7 million was recognized in respect of research and development tax credits in the three months ended March 31, 2025 (three months ended March 31, 2024: $2.5 million).
The current asset at March 31, 2025 was $16.8 million, comprised of $2.7 million in respect of research and development activities for the three months ended March 31, 2025 and $14.1 millionin respect of the year ended
December 31, 2024. In the three months ended, March 31, 2025, the Group received $11.0 million related to the receipt of the 2023 claim.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.